Svetlana F Lima, Silvia Pires, Amanda Rupert, Seun Oguntunmibi, Wen-Bing Jin, Andrew Marderstein, Gabriela Funez-dePagnier, Grace Maldarelli, Monica Viladomiu, Gregory Putzel, Wei Yang, Nancy Tran, Grace Xiang, Alex Grier, Chun-Jun Guo, Dana Lukin, Lisa A Mandl, Ellen J Scherl, Randy S Longman
Sulfasalazine is a prodrug known to be effective for the treatment of inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA), but the mechanistic role for the gut microbiome in regulating its clinical efficacy is not well understood. Here, treatment of 22 IBD-pSpA subjects with sulfasalazine identifies clinical responders with a gut microbiome enriched in Faecalibacterium prausnitzii and the capacity for butyrate production. Sulfapyridine promotes butyrate production and transcription of the butyrate synthesis gene but in F...
February 12, 2024: Cell reports medicine